Baseline characteristics of the 30 patients included in the trial
| Characteristic . | Patients (N = 30) . |
|---|---|
| Male/female | 17 (57%)/13 (43%) |
| Median (range) age, y | 49 (19-59) |
| ECOG score <2 | 27 (90%) |
| CNS involvement | 1 (3%) |
| Median (range) WBC count, ×109/L | 6.4 (0.6-359.3) |
| Median (range) hemoglobin, g/L | 9.0 (6.3-14.5) |
| Median (range) platelets, ×109/L | 38.5 (11.0-206.0) |
| Median (range) LDH, U/L | 358.5 (160.0-3278.0) |
| Median (range) BCR-ABL1/ABL ratio, % | 39.7 (0.073-2763.3) |
| Phenotype | |
| Early pre-B | 2 (7%) |
| Common | 27 (90%) |
| Pre-B | 1 (3%) |
| Cytogenetics | |
| t(9;22) isolated | 18 (60%) |
| t(9;22) with additional chromosomal abnormalities | 12 (40%) |
| BCR rearrangement (bone marrow) | |
| p190 | 20 (67%) |
| p210 | 9 (30%) |
| p230 | 1 (3%) |
| Characteristic . | Patients (N = 30) . |
|---|---|
| Male/female | 17 (57%)/13 (43%) |
| Median (range) age, y | 49 (19-59) |
| ECOG score <2 | 27 (90%) |
| CNS involvement | 1 (3%) |
| Median (range) WBC count, ×109/L | 6.4 (0.6-359.3) |
| Median (range) hemoglobin, g/L | 9.0 (6.3-14.5) |
| Median (range) platelets, ×109/L | 38.5 (11.0-206.0) |
| Median (range) LDH, U/L | 358.5 (160.0-3278.0) |
| Median (range) BCR-ABL1/ABL ratio, % | 39.7 (0.073-2763.3) |
| Phenotype | |
| Early pre-B | 2 (7%) |
| Common | 27 (90%) |
| Pre-B | 1 (3%) |
| Cytogenetics | |
| t(9;22) isolated | 18 (60%) |
| t(9;22) with additional chromosomal abnormalities | 12 (40%) |
| BCR rearrangement (bone marrow) | |
| p190 | 20 (67%) |
| p210 | 9 (30%) |
| p230 | 1 (3%) |
Data are presented as no. (%) unless otherwise indicated.
LDH, lactate dehydrogenase; WBC, white blood cell; WHO, World Health Organization.